Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
Fabi
A
A
Ferretti
G
G
Salesi
N
N
Papaldo
P
P
Carlini
P
P
Ciccarese
M
M
Di Cocco
B
B
Cecere
F
F
Nardoni
C
C
Felici
A
A
Cognetti
F
F
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D004317:Doxorubicin; D018719:Erb-b2 Receptor Tyrosine Kinases